Abbott’s SonicForce coronary device meets safety, effectiveness goals in clinical trial
- Abbott’s investigational SonicForce coronary device met the TECTONIC trial’s primary safety and effectiveness endpoints, showing low treatment failure and high procedural success.
- Results were presented today at the Transcatheter Cardiovascular Therapeutics conference in San Diego and published in JACC: Cardiovascular Interventions.
- The device uses acoustic pressure waves to crack coronary calcium before stenting; potential approval would expand Abbott’s coronary device portfolio.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611011545PR_NEWS_USPR_____CG86002) on November 01, 2026, and is solely responsible for the information contained therein.